In his article “Life Sciences Venture Capital-funds on the rise” in the april issue of VentureCapital magazine, Dr. Thiel reports about the success of European Life Sciences Venture Capital funds in 2016. Many large funds, such as the Endeavour Vision III-fund and Life Science Partners V-fund raised more than 200 mio. euros. Particulary pleasing from a German point of view was the first closing of the Earlybird HealthTech fund, as the public German health insurer Barmer GEK is represented here as an investor for the first time.

You can read the whole article here→ (German-language link)